Vimarsana
Biggest News Aggregation in the World

Page 3 - Union Tech Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Union Tech Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Union Tech Ventures Today - Breaking & Trending Today

Guardio Rolls Out AI-Based Browser Extension for Cybersecurity - Vimarsana News

Guardio Rolls Out AI-Based Browser Extension for Cybersecurity

Israeli technology startup Guradio has rolled out an AI-based browser extension that can protect enterprises from cyberattacks.

Guardio Rolls Out AI-Based Browser Extension for Cybersecurity - Vimarsana News

Guardio Rolls Out AI-Based Browser Extension for Cybersecurity

Israeli technology startup Guradio has rolled out an AI-based browser extension that can protect enterprises from cyberattacks.

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio - Vimarsana News

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio GlobeNewswire January 10, 2022 MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed Contacts:Media: Will Harris, VP Marketing, MeMedpr@me-med.com IR: Kfir Emmer, CFO, MeMedkfir.emmer@me-med.comMedia Contacts:Consilium Strategic CommunicationsMeMed@consilium-comms.com

MeMed raises $93 million to translate the immune system - Vimarsana News

MeMed raises $93 million to translate the immune system

The Israeli company recently received FDA approval for its MeMed BV test to help healthcare providers distinguish between bacterial and viral infections

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio - Vimarsana News

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV test recently cleared for use by US FDA to aid in distinguishing between bacterial and